Supplying vaccines to the U.S. and the world

Since Ceva acquired the Biomune Company in 2005, our production capabilities have steadily grown.

We currently supply more than 70 countries with critical vaccines. This growth means we’re continually investing in production, research and development. Since 2006, Ceva has invested over $65 million in our Lenexa campus.  Major projects completed include:

  • $18 million  - New vaccine manufacturing facility opened Nov. 2011
  • $  7 million  - New research and development facility opened June 2013
  • $10 million  - Expansion of vaccine manufacturing facility opened May 2015

We expect to invest an additional $30 million in the campus between now and 2017. 

Back to top